Detecting and targetting oncogenic fusion proteins in the genomic era

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Widespread cancer genome sequencing accelerates understanding of molecular aberrations in cancer.
• Bioinformatic methods and advancements in sequencing technology enable rapid identification of oncogenic fusion genes.

Purpose of the Study:

• To review major concepts in cancer pathogenesis derived from studying fusion proteins.
• To provide an overview of methods for identifying fusion proteins from next-generation sequencing (NGS) data.
• To discuss the validation of oncogenic potential and targeted therapies for fusion-driven cancers.

Main Methods:

• Review of literature on kinase fusions in liquid and solid tumors.
• Overview of bioinformatics tools for fusion gene identification from NGS data.
• Discussion of methods for validating oncogenic potential and therapeutic strategies.

Main Results:

• Fusion proteins, particularly kinase fusions, are key drivers in various cancers.
• Advances in sequencing and bioinformatics have significantly improved the detection of fusion genes.
• Targeted therapies show promise in treating cancers driven by specific fusion oncoproteins.

Conclusions:

• The study of fusion proteins has significantly advanced our understanding of cancer pathogenesis.
• Effective identification and validation methods are crucial for clinical application.
• Targeted therapies represent a promising avenue for treating fusion-driven malignancies.